Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compound formula for preventing and treating hyperhomocysteinemia (HHcy) by comprehensively correcting metabolic disorders

A cysteinemia and metabolic disorder technology, applied in the biological field, can solve the problems of severe cell ferroptosis, aggravate cardiovascular and cerebrovascular damage, and affect the effect of intervention, so as to reduce blood Hcy levels, correct metabolic disorders, and increase the effect. Effect

Inactive Publication Date: 2020-08-11
NORTHWEST A & F UNIV
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Reducing blood Hcy plays a very important role in improving the health of our people, but the existing HHcy prevention and treatment programs have many problems and defects, resulting in high incidence, cure rate and harmfulness of HHcy all year round
For example, patents such as application numbers CN201115679 and CN200710175651 use drugs or drug combinations to prevent and treat HHcy, requiring long-term administration or even injection of one or several drugs, resulting in low compliance of the intervention subjects, that is, it is difficult to persist because of the side effects of long-term use of drugs Use, affect the effect of the intervention
Patent applications such as CN201910452229 and CN201710910596 claim that the nutrients for HHcy prevention and treatment can be obtained from natural foods or vegetables, but the disclosed formula contains 1-10 mg of active iron, which is the core catalyst of the Fenton reaction and can induce HHcy Hydrogen peroxide is converted into highly oxidative hydroxyl radicals, which makes the ROS damage and cell ferroptosis caused by HHcy more serious, and aggravates the damage of HHcy to cardiovascular and cerebrovascular
[0006] More importantly, the current Hcy prevention and treatment plan does not fully consider the five pathways of Hcy metabolism, which leads to the poor effect of the current mainstream folic acid supplementation therapy on reducing Hcy; in addition, it is currently recognized that HHcy mainly damages cardiovascular and cerebrovascular endothelial cells , the inventor's previous cell experiments proved that HHcy induces ferroptosis in vascular endothelial cells, but all the treatment options retrieved by the inventor did not specifically protect HHcy-induced vascular endothelial damage, so the prevention and treatment effect is not good

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example 1 Formula effectiveness and safety evaluation experiments based on high-throughput cell experiments

[0022] On the basis of previous work, high-throughput experiments were used to screen out the optimal dosage of each component of this formula to form formula A: betaine (500 mg / d), calcium gluconate (1000 mg / d), folic acid (30 mg / d), vitamin B2 (10 mg / d), vitamin B6 (10 mg / d), vitamin B12 (50 μg / d) and α-tocopherol (20 mg / d).

[0023] Based on relevant documents and the previous work of the present invention, the corresponding ratio concentration of each component in the formula A is selected respectively (mass concentration ratio is according to the above order: 50:100:3:1:1:5:2, with betaine in When the final concentration in the culture solution is 0.01mmol / L, the formula A configured according to the above ratio is 1 U), and the cell viability is measured by the CCK8 method, and the T test analysis is carried out on the basis of the data of 5 independent ex...

Embodiment 2

[0024] Example 2 Randomized double-blind controlled multi-center volunteer experiment of this formula at a better concentration

[0025] From March 2018 to March 2019, in Beijing, Shanghai, and Xianyang, 50 volunteers with hyperHhyemia detected by physical examination in each city were selected (a total of 150 people, with an average age of 48.3 years, a male to female ratio of 1.17, Body mass index was 26.10, average blood Hhcy was 18.62 mmol / L), and formula A, food grade folic acid 40 mg and marketed formula B were taken daily for 60 days respectively (formula A was dosed according to Example 1, Formula B was taken according to the instructions, and it was taken after lunch), and the randomized double-blind control principle was used to conduct volunteer experiments. The results showed that formula A could finally reduce the blood HHy of volunteers by an average of 51.5%. The intervention effect of formula B was 2.28 times and 2.04 times. In addition, volunteers who took fol...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a compound formula for preventing and treating hyperhomocysteinemia (HHcy) by comprehensively correcting metabolic disorders. The compound formula includes the components of 300-1000 mg / d of glycine betaine, 500-2000 mg / d of calcium gluconate, 10-40 mg / d of folic acid, 5-15 mg / d of a vitamin B2, 5-15 mg / d of a vitamin B6, 20-80 [mu] g / d of a vitamin B12 and 10-50 mg / d of alpha-tocopherol. According to the formula, symptomatic prevention and treatment and cause prevention and treatment are integrated, and in the symptomatic aspect, target damage in a high homocysteine (Hcy) state of a current body is eliminated by relieving ROS damage and vascular endothelial cell viability reduction; in the cause aspect, the purpose of quickly reducing the blood Hcy level is achieved by comprehensively correcting five biochemical pathways involved in the folate metabolism disorder; in addition, a high-throughput cell experiment and a random double-blind control multi-center volunteer experiment are comprehensively utilized in formula development; and the action range and a toxicity threshold value of each component in the formula are accurately detected, so that the use dosage of each component has certain tolerance and extremely high safety, and the compound formula is suitable for serving as a core formula of a health care product or a dietary therapy nutritional supplement, and is beneficial to development and marketing of subsequent related products.

Description

technical field [0001] The invention belongs to the field of biotechnology and relates to a compound formula for preventing and treating hyperhomocysteinemia by comprehensively correcting metabolic disorders. Background technique [0002] Homocysteine ​​(Hcy) is an intermediate product of methionine metabolism in the body. Various metabolic disorders lead to abnormal accumulation of Hcy in the body. When plasma Hcy>15 μmol / L, it can be diagnosed as hyperhomocysteine Hyperhomocysteiemia (HHcy). HHcy can cause toxic damage to various tissues and organs such as cardiovascular and cerebrovascular, and is an independent risk factor for inducing various cardiovascular and cerebrovascular diseases. Large sample studies in cities have shown that H-type hypertension accounts for about 75% of Chinese hypertensive patients and is an important type of metabolic disease. [0003] HHcy is the result of the disorder of various metabolic pathways in the human body. Because the body its...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/205A61K31/191A61K31/519A61K31/525A61K31/4415A61K31/714A61K31/355A61P3/00A61P7/00
CPCA61K31/191A61K31/205A61K31/355A61K31/4415A61K31/519A61K31/525A61K31/714A61P3/00A61P7/00A61K2300/00
Inventor 贺鑫
Owner NORTHWEST A & F UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com